Abstract
Background and aim: Administration of 48 weeks of PEG-IFN alfa-2b and adefovir (ADV) combination therapy in chronically HBV infected patients resulted in a strong suppression of cccDNA, high rates of HBsAg seroconversion, and HBeAg seroconversion and loss, respectively (Wursthorn, EASL 2005). However, most HBV patients may need long-term antiviral therapy. The aim of the study is to determine virological and serological outcome including cccDNA in chronic Hepatitis B patients after 48 weeks of PEG-IFN alfa-2b and ADV therapy followed by 96 weeks of ADV mono therapy. Here we report on the interims analysis after 96 weeks of antiviral treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
